기업호재
Medtronic beats Q1, raises FY27 guidance to 7.25%-7.75%영어 원문
Multiple analysts confirm ~7% organic growth; new businesses like Cardiac Ablation add momentum
첫날 -0.5% · 5일 후 +0.8%
›전개 과정 2회
- 2026-09-09 Company lifts guidance, cites AI/robotics/ablation growth; margin pressure and competition remain challenges
- 2026-09-23 Multiple analysts confirm ~7% organic growth; new businesses like Cardiac Ablation add momentum
8-K 공시
8-K: 기타 주요 사항
첫날 -0.7% · 5일 후 -3.8%
이전 이벤트 15건›
제품호재
Medtronic's LigaSure Receives FDA Clearance for Hugo RAS영어 원문
FDA clearance expands robotic surgery applications, strengthening product portfolio
첫날 -1.2% · 5일 후 -3.6%
M&A·자금조달
Medtronic Launches Exchange Offer to Complete MiniMed Separation영어 원문
Shareholders can exchange shares; separation advances as MiniMed files S-4
첫날 +3.1% · 5일 후 -2.2%
실적호재
Medtronic Beats Q1 Estimates, Raises Guidance; Analysts Lift Forecasts영어 원문
Strongest revenue growth in a decade, driven by cardiovascular business
첫날 +1.4% · 5일 후 +3.2%
›전개 과정 4회
- 2026-08-28 Multiple sources confirm earnings date; analysts project EPS $1.39 and revenue $9.47B
- 2026-09-01 Revenue $9.76B beat, adj EPS $1.45 beat, raises FY27 profit and revenue outlook
- 2026-09-02 Q1 revenue and EPS beat, FY27 guidance raised, analysts follow
- 2026-09-04 Strongest revenue growth in a decade, driven by cardiovascular business
M&A·자금조달호재
Medtronic Expands Surgical Robotics Access via Cornerstone Robotics Partnership영어 원문
Partnership advances global surgical robotics footprint, strengthening minimally invasive surgery competitiveness
첫날 +1.5% · 5일 후 -0.2%
›전개 과정 3회
- 2026-09-01 Bolsters surgical robotics and heart valve innovation, strengthening growth platforms
- 2026-09-02 After investment, strategic partnership aims to increase global access
- 2026-09-03 Partnership advances global surgical robotics footprint, strengthening minimally invasive surgery competitiveness
8-K 공시
8-K: 실적 공시
첫날 +1.5% · 5일 후 -0.2%
실적
실적 발표
첫날 +1.5% · 5일 후 -0.2%
기업
Medtronic declares $0.72 per share cash dividend for Q2 FY2027영어 원문
Board approves quarterly dividend, continuing shareholder return policy
첫날 -1.9% · 5일 후 -2.5%
실적
실적 발표
첫날 +1.6% · 5일 후 -1.0%
제품호재
Medtronic Expands CE Mark for Affera System to Ventricular Arrhythmias영어 원문
Additional independent source confirms the CE Mark expansion, reinforcing the product milestone
첫날 -0.1% · 5일 후 +5.4%
›전개 과정 2회
- 2026-08-06 Sphere-9 first to get CE mark for ventricular ablation, offering new minimally invasive option
- 2026-08-06 Additional independent source confirms the CE Mark expansion, reinforcing the product milestone
애널리스트
UBS: 투자의견 상향 → Buy
첫날 +3.2% · 5일 후 -0.8%
제품호재
Medtronic to Unveil AI Surgical Platform Touch Surgery Aide영어 원문
FDA-cleared real-time AI on NVIDIA infrastructure marks new era in surgery
첫날 -1.1% · 5일 후 +5.5%
M&A·자금조달악재
Swedish Pension Fund Trims Medtronic Stake by 3.9% in Q1영어 원문
Institutional stake reduction signals portfolio rebalancing, though modest
첫날 -1.1% · 5일 후 +5.5%
M&A·자금조달호재
Decker Wealth Opens $5.08M Position in Medtronic in Q1영어 원문
13F filing reveals new institutional stake, indicating fund flow
첫날 +0.1% · 5일 후 +1.1%
실적
Medtronic to Report Q1 FY2027 Results on September 1영어 원문
Company sets official date for Q1 FY2027 earnings release
첫날 +0.1% · 5일 후 +1.1%
M&A·자금조달호재
Medtronic completes SPR acquisition, expanding pain therapy portfolio영어 원문
Adds category-defining SPRINT PNS technology to broadest pain therapy portfolio
첫날 +3.8% · 5일 후 -1.9%
방향별 정리 · 원문 링크
최근 2주간 X 신뢰 작성자 의견을 AI가 묶은 주장이며, 수치는 독립 작성자 수다. 언급량은 방향을 예측하지 않는다 · 투자 권유 아님
첫 댓글을 남겨 보세요
서로 존중 · 의견은 작성자 본인 책임 · 투자 권유 아님
사실과 의견을 구분해 표시 · 모든 항목 원문 확인 가능 · 본 정보는 투자 권유를 목적으로 하지 않으며, 투자 판단과 그 결과에 대한 책임은 투자자 본인에게 있습니다.
